Clinical Translation of Brain-Computer Interface in China: A Landscape Analysis of Investigator-Initiated Trials, Registered Clinical Trials, and Regulatory Approval

2026-07-08

AI Summary

Current therapies struggle to reverse motor or communication impairments caused by stroke, spinal cord injury, and neurodegenerative diseases, underscoring the urgent need for novel interventions. This study systematically integrates three data streams from China’s brain–computer interface (BCI) landscape—investigator-initiated trials, registered clinical trials, and regulatory-approved products—to quantitatively map, for the first time, the end-to-end translational pathway from research to clinical application. The analysis reveals distinct patterns in regional distribution, BCI modality (non-invasive approaches dominated by EEG; invasive methods including closed-loop deep brain stimulation and local field potential recording), and target indications (with a strong focus on post-stroke rehabilitation). Notably, the world’s first semi-invasive implanted BCI product has received regulatory approval. By June 2026, China had registered 134 BCI clinical trials, 26 investigator-initiated studies, and secured National Medical Products Administration approval for five BCI devices, reflecting markedly accelerated clinical translation.

Abstract

Neurological injury affects hundreds of millions of people worldwide, yet the loss of motor or communication functions resulting from stroke, spinal cord injury, and neurodegenerative disease remains largely irreversible with existing therapies. Brain-computer interfaces (BCIs) offer a promising pathway for restoring these functions by decoding neural activity into commands that control an external device. Here, we present the first quantitative analysis of China's BCI translational ecosystem, integrating evidence from three pillars: investigator-initiated trials (IITs), registered clinical trials, and regulatory-approved products. We analyzed 134 clinical trials from the Chinese Clinical Trial Registry (ChiCTR), 26 IITs, and five BCI-related products approved by the National Medical Products Administration as of June 2026. Results demonstrate that clinical trial registration has increased rapidly since 2020, with research centers concentrated primarily in Guangdong, Shanghai, and Jiangsu. Non-invasive systems predominated, accounting for 79.1% of registered studies, with stroke rehabilitation as the leading indication (65.0%). As of June 2026, five BCI-related products received regulatory approvals, including the world's first approved semi-invasive implantable BCI, an invasive closed-loop deep brain stimulation system with real-time local field potential recording, and three non-invasive EEG-based rehabilitation systems. Collectively, these findings characterize a rapidly expanding BCI translational pipeline in China, spanning from early clinical research to regulatory approval. However, long-term implant stability, standardization of clinical infrastructure and workflows, and generalizability of decoding algorithms remain critical barriers to widespread clinical adoption. Addressing these challenges will be essential for integrating BCI technologies into routine clinical practice.

Problem

• Brain-Computer Interface
• Clinical Translation
• Neurological Injury
• Regulatory Approval
• Motor Function Restoration

Innovation

• brain-computer interface
• clinical translation
• regulatory approval
• implantable BCI
• closed-loop neuromodulation